Endocrine Abstracts

Introduction: Hyperparathyroidism is common in patients with end-stage renal failure (ESRF): up to 20% require treatment for hyperparathyroidism within 10 years of commencing haemodialysis. Despite the significant cost of long-term medical treatment with calcimimetics and poor patient compliance, only a minority of patients are referred for surgery, usually due to their significant co-morbidity.Methods: Outcome data of patients with secondary or tertiary...